公告称，认购事项为集团提供较中国的商业银行一般所提供定期存款更高的回报;认购事项本金乃基于 集团临时闲置资金;认购事项以集团盈余现金储备(而非全球发售所得款项)拨付资金，因此不会影响集团 的营运资金状况或营运;及低风险的适当理财有利于集团加强资本利用及增加闲置资金收入。 北森控股(09669)发布公告，于2025年9月29日，集团向中国银行认购一款理财产品，金额为人民币1亿 元。截至本公告日期，包括本次中国银行认购事项在内，中国银行认购事项的未结付本金总额为人民币 3.6亿元。 ...

公告称，认购事项为集团提供较中国的商业银行一般所提供定期存款更高的回报;认购事项本金乃基于 集团临时闲置资金;认购事项以集团盈余现金储备(而非全球发售所得款项)拨付资金，因此不会影响集团 的营运资金状况或营运;及低风险的适当理财有利于集团加强资本利用及增加闲置资金收入。 智通财经APP讯，北森控股(09669)发布公告，于2025年9月29日，集团向中国银行认购一款理财产品， 金额为人民币1亿元。截至本公告日期，包括本次中国银行认购事项在内，中国银行认购事项的未结付 本金总额为人民币3.6亿元。 ...

Core Viewpoint - The company, Chaoyu Eye Care (02219), announced that its indirect wholly-owned subsidiary, Chaoyu Medical Technology, will further subscribe to a financial product from the Bank of China with a total principal amount of RMB 240 million, scheduled for September 26, 2025 [1] Group 1 - The total principal amount of the financial product subscription is RMB 240 million [1]

Group 1 - The company, Chaoyou Eye Care (02219), announced that its indirect wholly-owned subsidiary, Chaoyou Medical Technology, will further subscribe to a financial product from the Bank of China with a total principal amount of RMB 240 million by September 26, 2025 [1]

Group 1 - The company, Chaoyu Eye Care (02219.HK), announced a further subscription of RMB 240 million in wealth management products from the Bank of China, scheduled for September 26, 2025 [1] - The subscription will be funded by the group's surplus cash rather than proceeds from a global offering [1]

Core Viewpoint - The company, Chaoyu Eye Care (02219), announced that its indirect wholly-owned subsidiary, Chaoyu Medical Technology, will further subscribe to a financial product from the Bank of China with a total principal amount of RMB 30 million, funded by the group's surplus cash rather than proceeds from a global offering [1] Group 1 - The subscription amount for the financial product is RMB 30 million [1] - The funding for this subscription comes from the company's surplus cash [1] - The subscription is scheduled for August 22, 2025 [1]

Group 1 - The company, Chaoyu Eye Care (02219), announced that on August 22, 2025, its indirect wholly-owned subsidiary, Chaoyu Medical Technology, will further subscribe to a financial product from the Bank of China with a total principal amount of RMB 30 million [1] - The subscription will be funded by the group's surplus cash rather than proceeds from a global offering [1]

Group 1 - The core point of the article is that Chaogu Medical Technology, a wholly-owned subsidiary of Chaogu Eye Care, has further subscribed to a financial product from the Bank of China with a total principal amount of RMB 30 million, effective August 22, 2025 [1]